Michaela Koehm, ACR 2021: Methotrexate Effect on bDMARDs in the Treatment of Active PsA
We were delighted to speak with Dr. Michaela Koehm (Goethe University, Frankfurt am Main, Germany) to discuss her trial investigating the effect of methotrexate on ustekinumab treatment for active psoriatic arthritis.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘Neither Add-on nor Withdrawal of Methotrexate Impacts Efficacy of IL12/23 Inhibition in Active PsA: Data from a Multicenter Investigator-initiated Randomized Placebo-controlled Clinical Trial on Arthritis, Dactylitis, Enthesitis, Psoriasis, QoL and Function.’ (ABSTRACT NUMBER: L12) was presented at the ACR Convergence, 5-9 November 2021.
- What is the rationale for combining methotrexate with a biological disease-modifying antirheumatic drug (DMARD) in the treatment of active psoriatic arthritis (PsA)? (0:20)
- What were the aims and design of the clinical trial you are presenting? (1:01)
- What were the efficacy and safety findings of the study? (1:40)
- Why do you think methotrexate had no effect on the efficacy of ustekinumab? (2:15)
- What questions remain unanswered and what future studies are planned? (4:04)
Disclosures: Michaela Koehm discloses receiving a research grant from Janssen.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the virtual ACR Convergence 2021.
